See more : Henderson Land Development Company Limited (HLDCY) Income Statement Analysis – Financial Results
Complete financial analysis of ViewRay, Inc. (VRAY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ViewRay, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Companhia Energética de Pernambuco – CELPE (CEPE3.SA) Income Statement Analysis – Financial Results
- LatAmGrowth SPAC (LATGU) Income Statement Analysis – Financial Results
- Tex-Ray Industrial Co., Ltd. (1467.TW) Income Statement Analysis – Financial Results
- Amco India Limited (AMCOIND.BO) Income Statement Analysis – Financial Results
- Archimedes Tech SPAC Partners Co. (ATSPW) Income Statement Analysis – Financial Results
ViewRay, Inc. (VRAY)
About ViewRay, Inc.
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 102.21M | 70.12M | 57.02M | 87.78M | 80.96M | 34.04M | 22.24M | 10.39M | 0.00 | 3.16M |
| Cost of Revenue | 92.16M | 69.78M | 61.08M | 93.26M | 74.36M | 27.71M | 25.87M | 14.54M | 0.00 | 8.19M |
| Gross Profit | 10.05M | 335.00K | -4.06M | -5.48M | 6.60M | 6.33M | -3.63M | -4.15M | 0.00 | -5.03M |
| Gross Profit Ratio | 9.83% | 0.48% | -7.12% | -6.24% | 8.16% | 18.60% | -16.32% | -39.98% | 0.00% | -159.16% |
| Research & Development | 32.43M | 31.85M | 25.01M | 23.79M | 16.52M | 14.71M | 11.44M | 10.45M | 0.00 | 8.78M |
| General & Administrative | 52.44M | 56.09M | 61.73M | 65.72M | 50.11M | 31.38M | 23.50M | 21.69M | 0.00 | 9.51M |
| Selling & Marketing | 30.49M | 16.04M | 15.18M | 25.81M | 15.06M | 8.41M | 5.60M | 5.14M | 0.00 | 3.78M |
| SG&A | 82.93M | 72.14M | 76.91M | 91.52M | 65.18M | 39.79M | 29.10M | 26.82M | 0.00 | 13.29M |
| Other Expenses | 3.17M | -2.17M | 585.00K | 3.20M | 6.39M | -16.77M | -512.00K | -117.00K | 0.00 | 0.00 |
| Operating Expenses | 115.36M | 103.98M | 101.92M | 115.32M | 81.70M | 54.50M | 40.55M | 37.27M | 0.00 | 22.07M |
| Cost & Expenses | 207.52M | 173.77M | 162.99M | 208.58M | 156.05M | 82.21M | 66.41M | 51.82M | 0.00 | 30.26M |
| Interest Income | 1.69M | 13.00K | 791.00K | 1.72M | 8.00K | 5.00K | 2.00K | 2.00K | 0.00 | 4.00K |
| Interest Expense | 5.06M | 4.24M | 3.31M | 4.33M | 7.70M | 7.25M | 5.95M | 3.45M | 0.00 | 97.00K |
| Depreciation & Amortization | 4.85M | -2.16M | 1.38M | 4.92M | 3.50M | 2.20M | 1.71M | 1.26M | 0.00 | 1.15M |
| EBITDA | -100.46M | -105.81M | -104.60M | -115.87M | -68.70M | -62.73M | -44.69M | -41.54M | 0.00 | -26.04M |
| EBITDA Ratio | -98.29% | -150.90% | -183.46% | -132.00% | -84.85% | -184.28% | -200.95% | -399.83% | 0.00% | -824.34% |
| Operating Income | -107.13M | -103.65M | -105.98M | -120.80M | -75.09M | -48.16M | -44.18M | -41.43M | 0.00 | -27.10M |
| Operating Income Ratio | -104.81% | -147.82% | -185.87% | -137.61% | -92.75% | -141.48% | -198.66% | -398.72% | 0.00% | -857.77% |
| Total Other Income/Expenses | -203.00K | -6.40M | -1.93M | 596.00K | -1.30M | -24.01M | -6.46M | -3.57M | 0.00 | -125.00K |
| Income Before Tax | -107.33M | -110.05M | -107.91M | -120.20M | -76.40M | -72.18M | -50.64M | -44.99M | 0.00 | -27.22M |
| Income Before Tax Ratio | -105.01% | -156.94% | -189.26% | -136.93% | -94.36% | -212.02% | -227.71% | -433.05% | 0.00% | -861.73% |
| Income Tax Expense | 203.00K | -3.91M | -2.53M | 2.87M | 1.30M | -9.52M | 3.73M | 1.00K | 0.00 | 0.00 |
| Net Income | -107.53M | -106.13M | -105.38M | -123.07M | -76.40M | -72.18M | -50.64M | -45.00M | 0.00 | -27.22M |
| Net Income Ratio | -105.21% | -151.36% | -184.82% | -140.20% | -94.36% | -212.02% | -227.71% | -433.06% | 0.00% | -861.73% |
| EPS | -0.60 | -0.65 | -0.71 | -1.21 | -0.94 | -1.23 | -1.26 | -2.58 | 0.00 | -33.39 |
| EPS Diluted | -0.60 | -0.65 | -0.71 | -1.21 | -0.94 | -1.23 | -1.26 | -2.58 | 0.00 | -33.39 |
| Weighted Avg Shares Out | 180.70M | 164.52M | 147.90M | 102.00M | 81.12M | 58.46M | 40.07M | 17.43M | 892.32K | 815.34K |
| Weighted Avg Shares Out (Dil) | 180.70M | 164.52M | 147.90M | 102.00M | 81.12M | 58.46M | 40.07M | 17.43M | 892.32K | 815.34K |
SUNY Upstate Cancer Center Chooses ViewRay's MRI-Guided Radiation Therapy System to Treat Cancer Patients
Becomes First Cancer Center in Upstate New York to offer the Advanced Precision of MRIdian® MRI-Guided Radiation Therapy DENVER , Oct. 6, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that SUNY Upstate Cancer Center in Syracuse, New York has...
San Pietro Fatebenefratelli Hospital Treats its 1,000th Patient with MRIdian® MRI-Guided Radiation Therapy
Italian hospital reaches patient milestone in less than three years using MRIdian's real-time, on-table adaptive capabilities DENVER , Oct. 4, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that San Pietro Fatebenefratelli Hospital in Rome has treated its 1,000th patient...
ViewRay to host Investor Day
DENVER , Oct. 3, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today plans to host an Investor Day on Thursday, November 17, 2022, at 8:00 a.m. Eastern Time in New York City, NY.
MD Anderson Cancer Center Selects ViewRay to Expand MR-Guided Radiation Therapy Program
First MRIdian system to be installed at MD Anderson main campus at the Texas Medical Center in Houston DENVER , Sept. 20, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the University of Texas MD Anderson Cancer Center...
ViewRay® to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
DENVER , Sept. 9, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the Morgan Stanley 20th Annual Global Healthcare Conference.
GenesisCare Purchases Two Additional ViewRay MRIdian MRI-guided Radiotherapy Systems for Guildford and Birmingham Projects, Doubling United Kingdom Footprint to Four Systems
New agreement expands access to precision radiotherapy to more cancer patients in the UK DENVER , Sept. 8, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that GenesisCare, the largest global provider of cancer services across the USA, UK,...
ViewRay Announces China NMPA Approval of its MRIdian® MRI-Guided Radiation Therapy for Cancer Patients
This approval expands MRIdian's global reach and offers cancer patients a new radiation therapy option—MRIdian SMART DENVER , Sept. 7, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the company's MRIdian MRI-Guided Radiation Therapy System has received approval from...
VA Houston Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services
This is the First Hospital in Texas and the Third VA Hospital to Offer MRIdian® MRI-guided Radiation Therapy Cancer Treatment. DENVER , Aug. 23, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the VA Houston Healthcare System has...
National Cancer Center Hospital in Tokyo Upgrades to MRIdian® Linac for MRI-Guided Radiation Therapy and has treated its first patients
Largest Cancer Center in Japan Enhances its Real-Time Soft-Tissue Tracking and On-Table Adaptive Delivery with MRIdian System CLEVELAND, Aug. 11, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the National Cancer Center Hospital (NCCH) of Japan has upgraded...
ViewRay Selects Denver for Headquarters
Innovative cancer therapy company to leverage Colorado bioscience talent resources DENVER , Aug. 8, 2022 /PRNewswire/ -- ViewRay, Inc . (Nasdaq: VRAY), a medical device company that designs, manufactures, and markets the MRIdian® radiation therapy system, announced today that it is moving...
Source: https://incomestatements.info
Category: Stock Reports